Scarica l'app Stockscreener
0.3923
3.23%
-0.0131
Dopo l'orario di chiusura:
.38
-0.0123
-3.14%
Precedente Chiudi:
$0.4054
Aprire:
$0.4054
Volume 24 ore:
133.58K
Relative Volume:
0.18
Capitalizzazione di mercato:
$17.29M
Reddito:
$45.91M
Utile/perdita netta:
$-4.62M
Rapporto P/E:
-2.7981
EPS:
-0.1402
Flusso di cassa netto:
$-21.51M
1 W Prestazione:
-52.15%
1M Prestazione:
-48.65%
6M Prestazione:
-52.85%
1 anno Prestazione:
-83.02%
Intervallo 1D:
$0.3642
$0.41
Intervallo di 1 settimana:
$0.3642
$0.83
Portata 52W:
$0.3642
$2.43
Equillium Inc Stock (EQ) Company Profile
Nome
Equillium Inc
Settore
Industria
Telefono
(858) 412-5302
Indirizzo
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Confronta EQ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.3923 | 17.29M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2021-10-29 | Ripresa | Stifel | Buy |
| 2021-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Equillium Inc Borsa (EQ) Ultime notizie
Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st
Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World
Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe
Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan
Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World
Equillium Stock Price, Quotes and Forecasts - Benzinga
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com
Equillium stock rallies 26% on itolizumab study data - MSN
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St
Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World
Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq
Healthy Upside Potential: Equillium Inc (EQ) - SETE News
Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Equillium reports positive Phase 2 ulcerative colitis study data - MSN
why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News
Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily
What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News
Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily
10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily
CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com
Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis - Indian Pharma Post
UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues
Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance
Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa
Equillium Inc Azioni (EQ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):